Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

31 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Optimization of rituximab for the treatment of diffuse large B-cell lymphoma (II): extended rituximab exposure time in the SMARTE-R-CHOP-14 trial of the german high-grade non-Hodgkin lymphoma study group.
Pfreundschuh M, Poeschel V, Zeynalova S, Hänel M, Held G, Schmitz N, Viardot A, Dreyling MH, Hallek M, Mueller C, Wiesen MH, Witzens-Harig M, Truemper L, Keller U, Rixecker T, Zwick C, Murawski N. Pfreundschuh M, et al. Among authors: poeschel v. J Clin Oncol. 2014 Dec 20;32(36):4127-33. doi: 10.1200/JCO.2013.54.6861. Epub 2014 Nov 17. J Clin Oncol. 2014. PMID: 25403207 Clinical Trial.
Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60).
Pfreundschuh M, Schubert J, Ziepert M, Schmits R, Mohren M, Lengfelder E, Reiser M, Nickenig C, Clemens M, Peter N, Bokemeyer C, Eimermacher H, Ho A, Hoffmann M, Mertelsmann R, Trümper L, Balleisen L, Liersch R, Metzner B, Hartmann F, Glass B, Poeschel V, Schmitz N, Ruebe C, Feller AC, Loeffler M; German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL). Pfreundschuh M, et al. Among authors: poeschel v. Lancet Oncol. 2008 Feb;9(2):105-16. doi: 10.1016/S1470-2045(08)70002-0. Epub 2008 Jan 15. Lancet Oncol. 2008. PMID: 18226581 Clinical Trial.
CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group.
Pfreundschuh M, Kuhnt E, Trümper L, Osterborg A, Trneny M, Shepherd L, Gill DS, Walewski J, Pettengell R, Jaeger U, Zinzani PL, Shpilberg O, Kvaloy S, de Nully Brown P, Stahel R, Milpied N, López-Guillermo A, Poeschel V, Grass S, Loeffler M, Murawski N; MabThera International Trial (MInT) Group. Pfreundschuh M, et al. Among authors: poeschel v. Lancet Oncol. 2011 Oct;12(11):1013-22. doi: 10.1016/S1470-2045(11)70235-2. Epub 2011 Sep 21. Lancet Oncol. 2011. PMID: 21940214 Clinical Trial.
The role of sex and weight on rituximab clearance and serum elimination half-life in elderly patients with DLBCL.
Müller C, Murawski N, Wiesen MH, Held G, Poeschel V, Zeynalova S, Wenger M, Nickenig C, Peter N, Lengfelder E, Metzner B, Rixecker T, Zwick C, Pfreundschuh M, Reiser M. Müller C, et al. Among authors: poeschel v. Blood. 2012 Apr 5;119(14):3276-84. doi: 10.1182/blood-2011-09-380949. Epub 2012 Feb 15. Blood. 2012. PMID: 22337718 Free article. Clinical Trial.
Suboptimal dosing of rituximab in male and female patients with DLBCL.
Pfreundschuh M, Müller C, Zeynalova S, Kuhnt E, Wiesen MH, Held G, Rixecker T, Poeschel V, Zwick C, Reiser M, Schmitz N, Murawski N. Pfreundschuh M, et al. Among authors: poeschel v. Blood. 2014 Jan 30;123(5):640-6. doi: 10.1182/blood-2013-07-517037. Epub 2013 Dec 2. Blood. 2014. PMID: 24297867 Free article. Clinical Trial.
Optimization of rituximab for the treatment of DLBCL (I): dose-dense rituximab in the DENSE-R-CHOP-14 trial of the DSHNHL.
Murawski N, Pfreundschuh M, Zeynalova S, Poeschel V, Hänel M, Held G, Schmitz N, Viardot A, Schmidt C, Hallek M, Witzens-Harig M, Trümper L, Rixecker T, Zwick C. Murawski N, et al. Among authors: poeschel v. Ann Oncol. 2014 Sep;25(9):1800-1806. doi: 10.1093/annonc/mdu208. Epub 2014 Jun 13. Ann Oncol. 2014. PMID: 24928834 Free article. Clinical Trial.
Association of NADPH oxidase polymorphisms with anthracycline-induced cardiotoxicity in the RICOVER-60 trial of patients with aggressive CD20(+) B-cell lymphoma.
Reichwagen A, Ziepert M, Kreuz M, Gödtel-Armbrust U, Rixecker T, Poeschel V, Reza Toliat M, Nürnberg P, Tzvetkov M, Deng S, Trümper L, Hasenfuss G, Pfreundschuh M, Wojnowski L. Reichwagen A, et al. Among authors: poeschel v. Pharmacogenomics. 2015;16(4):361-72. doi: 10.2217/pgs.14.179. Pharmacogenomics. 2015. PMID: 25823784
A novel lymphoma-associated macrophage interaction signature (LAMIS) provides robust risk prognostication in diffuse large B-cell lymphoma clinical trial cohorts of the DSHNHL.
Staiger AM, Altenbuchinger M, Ziepert M, Kohler C, Horn H, Huttner M, Hüttl KS, Glehr G, Klapper W, Szczepanowski M, Richter J, Stein H, Feller AC, Möller P, Hansmann ML, Poeschel V, Held G, Loeffler M, Schmitz N, Trümper L, Pukrop T, Rosenwald A, Ott G, Spang R; Emed Demonstrator Project; German High Grade Non-Hodgkin’s Lymphoma Study Group (DSHNHL). Staiger AM, et al. Among authors: poeschel v. Leukemia. 2020 Feb;34(2):543-552. doi: 10.1038/s41375-019-0573-y. Epub 2019 Sep 17. Leukemia. 2020. PMID: 31530861 Clinical Trial.
Four versus six cycles of CHOP chemotherapy in combination with six applications of rituximab in patients with aggressive B-cell lymphoma with favourable prognosis (FLYER): a randomised, phase 3, non-inferiority trial.
Poeschel V, Held G, Ziepert M, Witzens-Harig M, Holte H, Thurner L, Borchmann P, Viardot A, Soekler M, Keller U, Schmidt C, Truemper L, Mahlberg R, Marks R, Hoeffkes HG, Metzner B, Dierlamm J, Frickhofen N, Haenel M, Neubauer A, Kneba M, Merli F, Tucci A, de Nully Brown P, Federico M, Lengfelder E, di Rocco A, Trappe R, Rosenwald A, Berdel C, Maisenhoelder M, Shpilberg O, Amam J, Christofyllakis K, Hartmann F, Murawski N, Stilgenbauer S, Nickelsen M, Wulf G, Glass B, Schmitz N, Altmann B, Loeffler M, Pfreundschuh M; FLYER Trial Investigators; German Lymphoma Alliance. Poeschel V, et al. Lancet. 2019 Dec 21;394(10216):2271-2281. doi: 10.1016/S0140-6736(19)33008-9. Lancet. 2019. PMID: 31868632 Clinical Trial.
31 results